6 of 100
6. Alexion Pharmaceuticals
3-year average
Revenue Growth: 75%
Profit Growth: 82%
Total Return: 37%
The company's first product to reach the market, Soliris-which treats a rare, but life-threatening disease that basically destroys red blood cells-has been a success. Sales rose about 50% in the most recent quarter compared to the equivalent period in 2010. Soliris is the only drug treating the blood disease, which is called paroxysmal nocturnal hemoglobinuria, and Alexion is now exploring other uses for its compound in the hopes of expanding the market for the medication.

Meanwhile, Alexion acquired Taligen Therapeutics early this year as part of its efforts to expand and diversify its drug pipeline. That deal brought early-stage compounds for age-related macular degeneration. Alexion also purchased an investigational therapy from Orphatec Pharmaceuticals for a rare metabolic disease that affects newborns.
Get stock quote: ALXN
Revenue ($ millions): $589.5
Net Income ($ millions): $102.9
Industry: Health Care
Network with Alexion Pharmaceuticals
What businesses do you think are primed to grow in this economy?
From the September 26, 2011 issue.
Revenue and profit figures reflect the four quarters ended on or before April 30,2011.
Total return is through June 30, 2011.

Sturm Ruger & Co 848%
Cirrus Logic 340%
Hi-Tech Pharmacal 234%
Green Mountain Coffee Roasters 120%
Netflix 116%
Acme Packet 108%
To qualify, a company -- domestic or foreign -- must be trading on a major U.S. stock exchange; file quarterly reports to the SEC; have a minimum market... More
Current Issue
  • Give the gift of Fortune
  • Get the Fortune app
  • Subscribe
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited, nor the BBA LIBOR Contributor Banks, nor Reuters, can be held liable for any irregularity or inaccuracy of BBA LIBOR. Disclaimer. Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.